Lipid-lowering therapy after coronary revascularization.

[1]  J. Alpert,et al.  ACC/AHA guidelines for coronary artery bypass graft surgery , 1999 .

[2]  G. Breithardt,et al.  Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT). , 1999, European heart journal.

[3]  K. Endresen,et al.  Luminal loss and restenosis after coronary angioplasty. The role of lipoproteins and lipids. , 1999, European heart journal.

[4]  F. Ragmin.  Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999, The Lancet.

[5]  D. Waters,et al.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. , 1999, The New England journal of medicine.

[6]  J. Murray,et al.  ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. , 1999, Journal of the American College of Cardiology.

[7]  R. Kleiger,et al.  Correction: Outcomes in Patients with Acute Non-Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy. , 1998, The New England journal of medicine.

[8]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[9]  T. B. Investigators,et al.  Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) , 1997, Circulation.

[10]  RITA-2 trial participants.  Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial , 1997, The Lancet.

[11]  A. Gotto,et al.  Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). , 1997, The American journal of cardiology.

[12]  M. Kinoshita,et al.  Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty. , 1997, Circulation.

[13]  A. Voors,et al.  Progression of atherosclerosis after venous coronary artery bypass graft surgery: a 15-year follow-up study. , 1997, Catheterization and cardiovascular diagnosis.

[14]  N. Geller,et al.  Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. , 1997, Circulation.

[15]  M. Leon,et al.  Contribution of inadequate arterial remodeling to the development of focal coronary artery stenoses. An intravascular ultrasound study. , 1997, Circulation.

[16]  M. Leon,et al.  Intravascular ultrasound insights into mechanisms of stenosis formation and restenosis. , 1997, Cardiology clinics.

[17]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[18]  V. Fuster,et al.  Prevention of atherosclerosis in coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[19]  P. Libby,et al.  Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. , 1997, Circulation.

[20]  P. Libby,et al.  Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points , 1996, Current opinion in lipidology.

[21]  V. Marques,et al.  Treatment of hypercholesterolemia in patients undergoing multiple coronary angioplasties. , 1996, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[22]  Moor Dl,et al.  Percutaneous transluminal coronary angioplasty (PTCA) : Long-term outcome and aeromedical implications , 1996 .

[23]  P. Stone,et al.  Effect of Combination Therapy with Lipid-Reducing Drugs in Patients with Coronary Heart Disease and Normal Cholesterol Levels , 1996, Annals of Internal Medicine.

[24]  T. Tamura,et al.  [Ten-year follow-up of percutaneous transluminal coronary angioplasty]. , 1996, Journal of cardiology.

[25]  Robert L. Frye,et al.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.

[26]  H. Daida,et al.  Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. , 1996, Japanese heart journal.

[27]  J. O’Keefe,et al.  Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. , 1996, The American journal of cardiology.

[28]  H. Swan,et al.  Lipid lowering: the case for identifying and treating the high-risk patient. , 1996, Cardiology clinics.

[29]  O. Hess,et al.  Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. , 1995, Journal of the American College of Cardiology.

[30]  C. Cannon,et al.  One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. , 1995, Journal of the American College of Cardiology.

[31]  S. Pocock,et al.  Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery , 1995, The Lancet.

[32]  S. Ellis,et al.  Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. , 1995, Journal of the American College of Cardiology.

[33]  E. Topol,et al.  Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. , 1995, Circulation.

[34]  M. Pfeffer,et al.  Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. , 1995, The American journal of cardiology.

[35]  J. A. Painter,et al.  Atherosclerosis in angiographically "normal" coronary artery reference segments: an intravascular ultrasound study with clinical correlations. , 1995, Journal of the American College of Cardiology.

[36]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[37]  C. Ayers,et al.  Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. , 1995, Circulation.

[38]  W. Weintraub,et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.

[39]  W. O’Neill,et al.  Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. , 1994, The New England journal of medicine.

[40]  P. Serruys,et al.  Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. , 1994, Circulation.

[41]  D. Foley,et al.  Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. , 1994, Circulation.

[42]  D. Waters,et al.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. , 1994, Circulation.

[43]  Y. Hirota,et al.  The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty. , 1994, Japanese circulation journal.

[44]  S. Hosoda,et al.  Long-term prognosis of medically treated patients with acute myocardial infarction and one-vessel coronary artery disease. , 1994, The American journal of cardiology.

[45]  Stanley Azen,et al.  Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.

[46]  A. Voors,et al.  Venous Coronary Artery Bypass Surgery A 15‐Year Follow‐up Study , 1993, Circulation.

[47]  T. Inoue,et al.  The relationship between serum lipoprotein(a) and restenosis after initial elective percutaneous transluminal coronary angioplasty. , 1993, Japanese circulation journal.

[48]  P. Hartigan,et al.  A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. , 1992, The New England journal of medicine.

[49]  W. Little,et al.  The underlying coronary lesion in myocardial infarction: Implications f coronary angiography , 1991, Clinical cardiology.

[50]  O. Wiklund,et al.  Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. , 1991, European heart journal.

[51]  R. Sahni,et al.  Prevention of restenosis by lovastatin after successful coronary angioplasty. , 1991, American heart journal.

[52]  W. Keon,et al.  Coronary bypass graft fate: long-term angiographic study. , 1991, Journal of the American College of Cardiology.

[53]  W. Little,et al.  Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. , 1990, The American journal of cardiology.

[54]  J. Webb,et al.  Does percutaneous transluminal coronary angioplasty accelerate atherosclerotic lesions? , 1990, Catheterization and cardiovascular diagnosis.

[55]  J Pekkanen,et al.  Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. , 1990, The New England journal of medicine.

[56]  D. Blankenhorn.  Can atherosclerotic lesions regress? Angiographic evidence in humans. , 1990, The American journal of cardiology.

[57]  K. Kent,et al.  Recurrent ischemia more than 1 year after successful percutaneous transluminal coronary angioplasty. An analysis of the extent and anatomic pattern of coronary disease. , 1989, Circulation.

[58]  W. Santamore,et al.  Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? , 1988, Circulation.

[59]  D. Waters,et al.  Restenosis and progression of coronary atherosclerosis after coronary angioplasty. , 1988, Journal of the American College of Cardiology.

[60]  M. Hwang,et al.  Progression of coronary artery disease after percutaneous transluminal coronary angioplasty. , 1988, American heart journal.

[61]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[62]  C. Zarins,et al.  Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.

[63]  W. Keon,et al.  Coronary bypass graft fate. Angiographic study of 1,179 vein grafts early, one year, and five years after operation. , 1986, The Journal of thoracic and cardiovascular surgery.

[64]  F. Loop,et al.  Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. , 1985, The Journal of thoracic and cardiovascular surgery.

[65]  M. Frick,et al.  Progression of coronary artery disease in randomized medical and surgical patients over a 5-year angiographic follow-up. , 1983, The American journal of cardiology.

[66]  M. Bourassa,et al.  Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. , 1983, Circulation.

[67]  M. Hwang,et al.  Progression of Coronary Artery Disease in Medically and Surgically Treated Patients 5 Years After Randomization , 1981, Circulation.

[68]  M. Bourassa,et al.  Progression of Obstructive Coronary Artery Disease 5 to 7 Years After Aortocoronary Bypass Surgery , 1978, Circulation.

[69]  L. Wallentin,et al.  Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999 .

[70]  P. Serruys,et al.  A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. , 1999, European heart journal.

[71]  P. Libby,et al.  Inflammation, the endothelium, and the acute coronary syndromes. , 1998, Journal of cardiovascular pharmacology.

[72]  R H Selzer,et al.  Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. , 1996, Circulation.

[73]  L. Heinemann,et al.  [Risk factors in hyperlipidemic patients with coronary heart disease one year after PTCA]. , 1994, Zeitschrift fur Kardiologie.

[74]  K. Lee,et al.  Serum cholesterol in patients undergoing cardiac catheterization for suspected coronary artery disease: diagnostic and prognostic implications. , 1992, Annals of epidemiology.

[75]  R. Arora,et al.  Restenosis after transluminal coronary angioplasty: a risk factor analysis. , 1990, Catheterization and cardiovascular diagnosis.